AR113881A1 - Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia - Google Patents

Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia

Info

Publication number
AR113881A1
AR113881A1 ARP180103328A ARP180103328A AR113881A1 AR 113881 A1 AR113881 A1 AR 113881A1 AR P180103328 A ARP180103328 A AR P180103328A AR P180103328 A ARP180103328 A AR P180103328A AR 113881 A1 AR113881 A1 AR 113881A1
Authority
AR
Argentina
Prior art keywords
methods
compositions
treatment
immune disorders
blautia strain
Prior art date
Application number
ARP180103328A
Other languages
English (en)
Spanish (es)
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AR113881A1 publication Critical patent/AR113881A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
ARP180103328A 2017-11-14 2018-11-14 Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia AR113881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762585782P 2017-11-14 2017-11-14

Publications (1)

Publication Number Publication Date
AR113881A1 true AR113881A1 (es) 2020-06-24

Family

ID=64746632

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103328A AR113881A1 (es) 2017-11-14 2018-11-14 Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia

Country Status (7)

Country Link
US (2) US10493113B2 (enExample)
EP (1) EP3710023A1 (enExample)
JP (1) JP2021502964A (enExample)
CN (1) CN111601610A (enExample)
AR (1) AR113881A1 (enExample)
TW (1) TW201936203A (enExample)
WO (1) WO2019099482A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
CN116196425A (zh) 2016-09-27 2023-06-02 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
US11241461B2 (en) * 2017-08-29 2022-02-08 Evelo Biosciences, Inc. Treating cancer using a blautia strain
US10493113B2 (en) 2017-11-14 2019-12-03 Evelo Biosciences, Inc. Compositions and methods for treating disease using a Blautia strain
EP3746121A1 (en) * 2018-01-31 2020-12-09 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using lachnospiraceae bacteria
JP7340591B2 (ja) * 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CA3120709A1 (en) 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
US20220080001A1 (en) * 2019-01-16 2022-03-17 Board Of Regents, The University Of Texas System Methods and compositions for treating immune checkpoint inhibitor associated colitis
MX2021013776A (es) * 2019-05-10 2021-12-10 4D Pharma Res Limited Composiciones que comprenden cepas bacterianas.
WO2020252144A1 (en) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Secreted microbial extracellular vesicles
CN112442455B (zh) * 2019-09-03 2022-04-01 北京量化健康科技有限公司 具有防治高血脂症功能的布劳特氏菌以及产品组合物及其制备方法和应用
CN111304120B (zh) * 2020-02-24 2021-07-23 浙江大学 Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
AU2021280299B2 (en) 2020-05-28 2025-08-21 Trench Therapeutics, Inc. Airway medicaments
AR122610A1 (es) * 2020-06-11 2022-09-21 Evelo Biosciences Inc Composiciones y métodos para el tratamiento de enfermedades y trastornos usando vesículas extracelulares microbianas de oscillospiraceae
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
CN115768448A (zh) * 2020-06-11 2023-03-07 伊夫罗生物科学公司 使用马西里福涅拉氏菌治疗疾病和障碍的组合物和方法
CN113842497B (zh) * 2021-09-28 2022-05-17 太原理工大学 一种具有光控抗菌和自愈合功能的CuS@Cur杂化水凝胶敷料的制备方法
CN114225024B (zh) * 2021-12-29 2022-08-19 山东健袖生态科技有限公司 一种用于治疗疾病的益生菌药物
EP4494484A4 (en) 2022-03-18 2026-03-18 Meiji Co Ltd COMPOSITION FOR CONTROLLING THE PROLIFERATION OF COLLINSELLA BACTERIA AND ITS USE
WO2023192360A1 (en) * 2022-03-31 2023-10-05 Incelldx, Inc. Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same
US20250235433A1 (en) * 2022-04-19 2025-07-24 Cedars-Sinai Medical Center Methods of treating and diagnosing fatty liver disease
CN114806979A (zh) * 2022-06-29 2022-07-29 杭州师范大学附属医院(杭州市第二人民医院) 一种治疗非酒精性脂肪性肝病的益生菌复合物及其应用
CN116254198B (zh) * 2023-01-05 2024-03-26 中国科学院微生物研究所 一种布劳特氏菌及其应用
CN116549465B (zh) * 2023-04-26 2025-02-11 复旦大学附属中山医院 Aldh2小分子激动剂在制备治疗心血管疾病及其代谢性疾病的药物中的应用
JP7706190B2 (ja) * 2023-09-25 2025-07-11 オルト株式会社 ブラウティア属細菌
WO2025070280A1 (ja) * 2023-09-25 2025-04-03 オルト株式会社 ブラウティア属細菌
WO2025070283A1 (ja) * 2023-09-25 2025-04-03 オルト株式会社 ブラウティア属細菌を用いた免疫賦活剤
JP7706191B2 (ja) * 2023-09-25 2025-07-11 オルト株式会社 ブラウティア属細菌を用いた免疫賦活剤
CN117617181B (zh) * 2023-12-27 2025-10-28 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种系统性红斑狼疮小鼠模型的构建方法和应用
CN119709558B (zh) * 2025-02-26 2025-05-30 昆明医科大学第一附属医院(云南省皮肤病医院) 布劳特氏菌emf75-02b1b及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
AU2015353465B2 (en) * 2014-11-25 2021-07-29 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and GVHD
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US9492473B2 (en) * 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
EP3964234A1 (en) * 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
SI3240554T1 (sl) * 2015-06-15 2019-12-31 4D Pharma Research Limited, Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
HK1258531A1 (zh) * 2015-08-24 2019-11-15 努比约塔有限公司 使用粪源细菌群落来治疗微生态失衡的系统和方法
CN107083339B (zh) * 2017-03-01 2020-02-14 华中农业大学 防治仔猪腹泻的复合益生菌制剂及其制备方法和应用
US10493113B2 (en) * 2017-11-14 2019-12-03 Evelo Biosciences, Inc. Compositions and methods for treating disease using a Blautia strain

Also Published As

Publication number Publication date
TW201936203A (zh) 2019-09-16
JP2021502964A (ja) 2021-02-04
US20190216862A1 (en) 2019-07-18
EP3710023A1 (en) 2020-09-23
CN111601610A8 (zh) 2023-07-21
WO2019099482A1 (en) 2019-05-23
US10493113B2 (en) 2019-12-03
US10702561B2 (en) 2020-07-07
CN111601610A (zh) 2020-08-28
US20200030389A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CO2020007142A2 (es) Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CN111601610A8 (zh) 使用布劳特氏菌属菌株治疗疾病的组合物和方法
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
EA201691582A1 (ru) Новые фармацевтические препараты
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX2017005030A (es) Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.
MX2018006637A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2021015632A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
EA201991997A1 (ru) Комбинированная терапия
NZ743049A (en) Anti-cd3-folate conjugates and their uses
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX395492B (es) Usos terapeuticos de l-4 cloroquinurenina.
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure